国药一致(000028) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was CNY 18.68 billion, an increase of 2.65% year-on-year[2]. - The net profit attributable to shareholders for Q3 2024 was CNY 322.05 million, a decrease of 10.39% year-on-year[2]. - For the first nine months of 2024, the company achieved an operating revenue of CNY 56.47 billion, a slight decline of 0.21% year-on-year[2]. - The basic earnings per share for Q3 2024 was CNY 0.58, down 10.77% compared to the same period last year[2]. - The company's net profit attributable to shareholders increased to CNY 12.99 billion, up from CNY 12.31 billion, reflecting a growth of approximately 5.5%[13]. - Net profit for Q3 2024 was CNY 1.10 billion, down from CNY 1.45 billion in Q3 2023, representing a decrease of approximately 24.4%[14]. - The company reported a total comprehensive income of CNY 1.10 billion for Q3 2024, compared to CNY 1.45 billion in the same period last year, indicating a decline of approximately 24.4%[15]. - Basic earnings per share for Q3 2024 were CNY 1.91, down from CNY 2.14 in Q3 2023, reflecting a decrease of about 10.7%[15]. Segment Performance - The distribution segment reported an operating revenue of CNY 40.84 billion for the first nine months, a growth of 3.20% year-on-year[3]. - The retail segment, however, saw a decline in operating revenue to CNY 16.40 billion, down 7.47% year-on-year[3]. - The company reported a net loss of CNY 39 million in the retail segment for the first nine months, a significant decrease of 110.36% year-on-year[3]. Assets and Liabilities - The total assets at the end of Q3 2024 were CNY 51.98 billion, representing a 9.27% increase from the end of the previous year[2]. - Total assets increased to CNY 51.98 billion as of September 30, 2024, up from CNY 47.57 billion at the beginning of the period, representing an increase of approximately 9.9%[12]. - Current assets totaled CNY 40.68 billion, compared to CNY 36.37 billion at the start of the period, reflecting a growth of about 11.9%[12]. - Total liabilities reached CNY 30.33 billion, compared to CNY 26.59 billion, which is an increase of approximately 14.5%[13]. - The company's liabilities increased by CNY 2.5591 million, a growth rate of 90.08%, primarily due to provisions for potential losses from pending litigation[7]. Cash Flow and Investments - The cash flow from operating activities for the first nine months decreased by 12.58% year-on-year, totaling CNY 1.28 billion[2]. - Cash flow from operating activities for Q3 2024 was CNY 1.28 billion, compared to CNY 1.47 billion in Q3 2023, a decline of approximately 12.5%[16]. - Cash inflow from investment activities increased by CNY 52.5144 million, a growth rate of 31.93%, primarily due to increased dividends from joint ventures[8]. - Cash paid for investments increased by CNY 8.8705 million, a growth rate of 192.35%, mainly due to remaining investment payments to a joint venture[8]. - The net cash flow from financing activities was -CNY 1,986,223,401.30, slightly improved from -CNY 2,014,650,640.63 in the previous period[17]. - The company reported a net cash decrease of CNY 777,563,840.97, compared to a decrease of CNY 614,614,173.85 in the previous period[17]. Expenses - Total operating costs for Q3 2024 were approximately CNY 55.38 billion, compared to CNY 50.33 billion in Q3 2023, reflecting an increase of about 10.1% year-over-year[14]. - Financial expenses rose by CNY 58.9558 million, a growth rate of 47.51%, mainly due to an increase in payable financing scale and corresponding interest expenses[7]. - The financial expenses, including interest expenses, rose to CNY 183.06 million in Q3 2024 from CNY 124.10 million in Q3 2023, an increase of approximately 47.5%[14]. - Research and development expenses increased to CNY 19.24 million in Q3 2024 from CNY 17.96 million in Q3 2023, marking a growth of about 7%[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,954, with the largest shareholder, China National Pharmaceutical Group, holding 56.06%[9]. - The net profit attributable to minority shareholders decreased by CNY 230.4040 million, a decline of 88.44%, mainly due to a decrease in net profit from the subsidiary[7].